Share on StockTwits

Repligen Corp. (NASDAQ:RGEN) SVP James R. Rusche sold 30,000 shares of the company’s stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $20.19, for a total value of $605,700.00. Following the sale, the senior vice president now directly owns 121,270 shares in the company, valued at approximately $2,448,441. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Repligen Corp. (NASDAQ:RGEN) traded up 0.90% during mid-day trading on Tuesday, hitting $20.21. The stock had a trading volume of 415,025 shares. Repligen Corp. has a 52 week low of $7.37 and a 52 week high of $21.15. The stock has a 50-day moving average of $17.78 and a 200-day moving average of $14.92. The company has a market cap of $647.5 million and a P/E ratio of 35.83.

Repligen Corp. (NASDAQ:RGEN) last released its earnings data on Thursday, May 8th. The company reported $0.13 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.07 by $0.06. The company had revenue of $16.33 million for the quarter, compared to the consensus estimate of $15.14 million. The company’s quarterly revenue was down .8% on a year-over-year basis. Analysts expect that Repligen Corp. will post $0.28 EPS for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at Jefferies Group raised their price target on shares of Repligen Corp. from $20.00 to $22.00 in a research note on Wednesday, June 4th. They now have a “buy” rating on the stock.

Repligen Corporation is a United States-based life sciences company focused on the development, production and commercialization of products used in the process of manufacturing biological drugs.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.